BioVaxys Technology Income Statement

Financials in millions CAD. Fiscal year is November - October.

Millions CAD. Fiscal year is Nov - Oct.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Apr '24 Apr 30, 2024	Oct '23 Oct 31, 2023	Oct '22 Oct 31, 2022	Oct '21 Oct 31, 2021	Oct '20 Oct 31, 2020	Oct '19 Oct 31, 2019
Selling, General & Admin	1.93	2.12	2.34	4.12	0.42	0.18
Research & Development	0	0.13	0.96	0.73	0.24	-
Operating Expenses	2	2.4	3.8	5.98	1.01	0.18
Operating Income	-2	-2.4	-3.8	-5.98	-1.01	-0.18
Interest & Investment Income	-	-	-	0	0	-
Currency Exchange Gain (Loss)	-0.05	-0.03	-0.02	-0.02	-0	-0
Other Non Operating Income (Expenses)	-3.64	-4.03	-0.26	-0.46	-0.09	-0.03
EBT Excluding Unusual Items	-5.7	-6.46	-4.08	-6.46	-1.1	-0.22
Asset Writedown	-0.5	-1.45	-7.4	-	-	-
Other Unusual Items	0.93	0.21	-0.25	-	-	-
Pretax Income	-5.27	-7.69	-11.73	-6.46	-1.1	-0.22
Earnings From Continuing Operations	-5.27	-7.69	-11.73	-6.46	-1.1	-0.22
Earnings From Discontinued Operations	-	-	-	-	-0.07	-0.01
Net Income	-5.27	-7.69	-11.73	-6.46	-1.17	-0.23
Net Income to Common	-5.27	-7.69	-11.73	-6.46	-1.17	-0.23
Shares Outstanding (Basic)	147	134	98	83	28	10
Shares Outstanding (Diluted)	147	134	98	83	28	10
Shares Change (YoY)	30.95%	36.63%	18.39%	193.97%	171.64%	-
EPS (Basic)	-0.04	-0.06	-0.12	-0.08	-0.04	-0.02
EPS (Diluted)	-0.04	-0.06	-0.12	-0.08	-0.04	-0.02
Free Cash Flow	-0.46	-1.05	-1.57	-5.29	-1.23	-0.23
Free Cash Flow Per Share	-0.00	-0.01	-0.02	-0.06	-0.04	-0.02
EBIT	-2	-2.4	-3.8	-5.98	-1.01	-0.18
Advertising Expenses	-	-	0.17	1.72	0.08	-

Source: S&P Capital IQ. Standard template. Financial Sources.